Bimekizumab Long-Term On-Treatment Remission and Associated Sustained Improvements in Quality of Life in Moderate to Severe Plaque Psoriasis Across Five Phase 3/3b Trials
SKIN The Journal of Cutaneous Medicine · 11.05.2026 · 10 (3) · s772
DOI: 10.25251/pkdcct35 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 11.05.2026. Verfasst von Joseph F Merola und 9 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
In 2025, a National Psoriasis Foundation (NPF) consensus defined on-treatment remission in psoriasis as the continuous maintenance of either body surface area (BSA)=0% or Investigator’s Global Assessment (IGA)=0 for ≥6 months (NPF-defined on-treatment remission).1 Longer periods of on-treatment remission were also defined as ≥12 or ≥24 months to allow for benchmarking of more durable treatments.1 Here, we assessed whether patients with moderate to severe psoriasis treated with bimekizumab (BKZ), an interleukin (IL)-17A and IL-17F inhibitor, demonstrated long-term on-treatment remission and whether this was associated with improved quality of life, through 3 years. Procedure/study Data were pooled from the 52-week BE VIVID and 56-week BE SURE/BE READY phase 3 trials, their 144-week open-label extension (OLE) BE BRIGHT, and the 144-week BE RADIANT phase 3b trial.2–6 Patients included in this analysis were randomized to BKZ 320mg every 4 weeks (Q4W) to Week16, then received BKZ Q4W or Q8W into the OLEs, and completed 3 years with no missing BSA or IGA assessments (BKZ Total). A subgroup (BKZ Q4W/Q8W) received BKZ Q4W to Week16 then Q8W continuously thereafter (approved dosing regimen for most patients with psoriasis).7 The proportion of patients who achieved on-treatment remission for ≥6/≥12/≥24 months are reported based on two definitions: NPF-defined remission and continuous achievement of 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100 remission). Rates of Dermatology Life Quality Index (DLQI) 0/1, indicating no effect of skin disease on patients’ lives,8 are reported among patients achieving remission. All data are reported as observed.
Results
Overall, 615 BKZ Total patients and 207 BKZ Q4W/Q8W patients were included in this analysis. In the BKZ Total group, 87.8%/77.9%/57.2% achieved NPF-defined on-treatment remission for at least one ≥6/≥12/≥24-month period through Year3, respectively. Among BKZ Total patients who achieved ≥6/≥12/≥24-month NPF-defined on-treatment remission at any point (n=540/479/352), DLQI 0/1 rates were 78.3%/79.3%/82.1% at Week16, 90.9%/92.9%/95.7% at Year1, and 90.1%/93.1%/93.7% at Year3, respectively. Similar results were observed using PASI 100 on-treatment remission, and consistent findings were seen in the BKZ Q4W/Q8W subgroup.
Conclusion
Bimekizumab treatment over 3 years led to the achievement of long-term on-treatment remission in a high proportion of patients with moderate to severe psoriasis, resulting in considerable improvements in quality of life. This highlights bimekizumab’s long-term deep clinical control and its meaningful impact on patients.
Zitieren
APA
Merola, J. F., Armstrong, A., Balak, D. M., Hawkes, J. E., Kircik, L. H., Lovegrove, F. E., Herr, H., Jeffray, T., Kavanagh, S., & Langley, R. G. (2026). Bimekizumab Long-Term On-Treatment Remission and Associated Sustained Improvements in Quality of Life in Moderate to Severe Plaque Psoriasis Across Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine, 10(3), s772. https://doi.org/10.25251/pkdcct35
Vancouver
Merola JF, Armstrong A, Balak DM, Hawkes JE, Kircik LH, Lovegrove FE, et al. Bimekizumab Long-Term On-Treatment Remission and Associated Sustained Improvements in Quality of Life in Moderate to Severe Plaque Psoriasis Across Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 2026;10(3):s772. doi:10.25251/pkdcct35
BibTeX
@article{Merola2026,
author = {Merola, Joseph F and Armstrong, April and Balak, Deepak MW and Hawkes, Jason E and Kircik, Leon H and Lovegrove, Fiona E and Herr, Heather and Jeffray, Treena and Kavanagh, Sarah and Langley, Richard G},
title = {Bimekizumab Long-Term On-Treatment Remission and Associated Sustained Improvements in Quality of Life in Moderate to Severe Plaque Psoriasis Across Five Phase 3/3b Trials},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {3},
pages = {s772},
doi = {10.25251/pkdcct35}
}
EUVIMED